Asthma News

News

Dupilumab benefits in kids with asthma hold out to 52 weeks

A healthy heart prevents adult-onset asthma: study

20240116110000

Maintaining good cardiovascular health (CVH) can help avert incident adult-onset asthma (AOA) regardless of a person’s asthma genetic risks, according to a study.

Singapore faces high asthma burden

Jairia Dela Cruz, 20240105140000

Singapore is disproportionately burdened by asthma, with related hospitalizations and emergency department (ED) visits occurring twice as often as the average of other developed countries, according to a study.

Nocturnal reflux, snoring linked to increased risk of asthma, respiratory problems

20231222060000

People with nocturnal gastroesophageal reflux (GER) and habitual snoring are vulnerable to developing asthma and respiratory symptoms, according to a study.

Benralizumab appears superior to mepolizumab in severe eosinophilic asthma

Stephen Padilla, 20231212120000

Both mepolizumab and benralizumab are effective in improving the clinical outcomes of patients with severe eosinophilic asthma, as shown in a recent study. However, treatment with benralizumab appears to be better than mepolizumab in reducing exacerbations, improving forced expiratory volume, and depleting blood eosinophils.

Simplified, tailored treatment for asthma improves patient outcomes

Audrey Abella, 20231129100000

Asthma is a highly prevalent disease that can affect anybody regardless of age, race, and location. The overall burden of asthma remains severe. Despite the range of available therapies and well-established guidelines, there remains a significant unmet need in the management of asthma. [BMC Public Health 2012;12:860; Respir Res 2023;24:169; Eur Respir J 2014;43:343-373]

Comprehensive approach needed for better asthma care

Jairia Dela Cruz, 20231126080000

Simply developing evidence-based recommendations is not enough to improve asthma care. These recommendations should also be disseminated and implemented at national and local levels, then integrated into routine clinical practice to have a positive effect on patient outcomes, according to an expert.

Treatment choices influence rescue medication use in asthma

Jairia Dela Cruz, 20231125140000

In patients with poor asthma control, switching from fluticasone propionate (FP) monotherapy to inhaled corticosteroid (ICS) plus a long-acting beta-agonist (LABA) combination therapy may help improve symptom control and reduce the use of reliever or rescue medications, according to a study.

Lack of awareness about biologics for asthma widespread among primary care doctors

Jairia Dela Cruz, 20231123140000

Many primary care physicians (PCPs) appear to be inadequately informed about the role of biologics in managing asthma, as shown in a study.

Asthma may up risk of hospitalization in kids with COVID-19

Asthma education, control test help lower exacerbations risks

Stephen Padilla, 20231123120000

The presence of asthma education and Asthma Control Test (ACT) may prevent exacerbations or at least delay the onset of severe exacerbations, suggests a Singapore study.

Dupilumab, ruxolitinib deliver benefits to atopic dermatitis patients

Stephen Padilla, 20231117130000

Treatment with dupilumab increases the levels of bone alkaline phosphatase (BALP), a marker of bone mineralization, in paediatric patients with moderate-to-severe atopic dermatitis (AD), regardless of asthma comorbidity, reports a study presented at ACAAI 2023.

Mepolizumab: Targeting eosinophils in severe asthma with precision medicine

Pearl Toh, 16 Sep 2020

Mepolizumab, a first-in-class anti-IL-5* antibody, effectively prevents asthma exacerbations in patients with severe eosinophilic asthma (SEA), according to a presentation at the ERS 2020 Congress.

Kids hard-hit by Delta; which ART performs best?

Elvira Manzano, 24 Oct 2021

That COVID-19 mostly spared children might be changing. The Delta variant has taken a severe, unthinkable toll on kids – at least in Arkansas, US, reports an expert at IDWeek 2021.

Long COVID: What we have learned so far

Prof. Ghassan Dbaibo, 27 Apr 2023

The WHO defines long COVID as a condition that occurs 3 months from COVID-19 onset, whose symptoms last ≥2 months and cannot be attributed to an alternative diagnosis. In an interview with MIMS Doctor, Professor Ghassan Dbaibo of the Center for Infectious Diseases, American University of Beirut, Beirut, Lebanon, describes the evolving attitudes towards long COVID among healthcare professionals (HCPs), some unexpected predisposing factors, potential biological mechanisms behind prolonged symptom duration and shares data on vaccination’s protective effects against long COVID.